The FDA's reclassification of desiccated thyroid extract as a biologic isn't background noise — it's an active threat that could cut off access for millions of patients who rely on it when synthetic alternatives haven't worked. When that happens, compounding pharmacies will be the first call. The question is whether you'll be ready to have that conversation.
APC's June 25 webinar with Dr. Sarah Zielsdorf, MD, is the preparation you need. She'll trace how desiccated thyroid extract went from the standard of care for hypothyroidism to a medication most prescribers were never trained on — and why the pharmaceutical industry had every incentive to keep it that way. You'll leave with a clear picture of the emerging research, the regulatory threat on the table, and what compounding professionals should be doing right now. If you compound desiccated thyroid extract or work with prescribers who should be recommending it, this is not one to skip. Register here.